CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank33
3Y CAGR-15.1%
5Y CAGR-9.6%
Year-over-Year Change
Research and development spending
3Y CAGR
-15.1%/yr
vs +1.8%/yr prior
5Y CAGR
-9.6%/yr
Recent deceleration
Acceleration
-17.0pp
Decelerating
Percentile
P33
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $68.26M | -18.1% |
| 2024 | $83.38M | +7.3% |
| 2023 | $77.68M | -30.4% |
| 2022 | $111.65M | -2.2% |
| 2021 | $114.19M | +1.1% |
| 2020 | $112.94M | -14.2% |
| 2019 | $131.62M | +26.7% |
| 2018 | $103.87M | +12.6% |
| 2017 | $92.28M | +68.5% |
| 2016 | $54.76M | - |